Growth, Trends, and Opportunities in the Therapeutic Plasma Exchange Market: Key Insights for the Next Decade
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
What is the Long-Term Projected Growth Rate for the Therapeutic Plasma Exchange Market, and What Are the Key Drivers?
The market for therapeutic plasma exchange has witnessed significant expansion in the past few years. The market, which currently stands at $1.47 billion in 2024, is projected to increase to $1.62 billion by 2025, reflecting a compound annual growth rate (CAGR) of 9.8%. This robust growth during the previous years is linked to the rise of immunological diseases, advancements in technology, heightened awareness and education, broader indications, as well as a better comprehension of pathophysiology.
The market size for therapeutic plasma exchange is projected to witness substantial expansion in the upcoming years, estimated to reach $2.32 billion by the year 2029, with a compound annual growth rate (CAGR) of 9.5%. This growth during the forecast period can be credited to various factors such as an increasing elderly population, clinical research and guidelines, regulatory frameworks, advancements in hospital infrastructure and healthcare investments, healthcare spending, and reimbursement policies. Key trends observed during this forecast period encompass individualized treatments, implementation of automation, partnership initiatives, and the integration of telemedicine.
How Are the key drivers Contributing to the Expansion of the Therapeutic Plasma Exchange Market?
The rise in hematological disorders is anticipated to boost the therapeutic plasma exchange market’s growth. Hematological disorders, also referred to as blood disorders, are ailments affecting the blood and tissues that form blood such as lymph nodes, spleen, and bone marrow. The increase in these disorders is attributed to factors like genetic predispositions, environmental impacts, and lifestyle modifications. Therapeutic plasma exchange (TPE) is beneficial in the treatment of hematological disorders as it aids in getting rid of pathogenic substances from the plasma. This includes autoantibodies in autoimmune hemolytic anemia or immune complexes in thrombotic thrombocytopenic purpura, helping to reduce disease severity and enhance patient outcomes. For instance, the Leukemia and Lymphoma Society, a professional organization based in the US, projected an approximate rise of 2.3% in myeloma diagnoses from 2021 to 2023 – increasing from 34,920 to 35,730 in August 2023. Thus, the increasing prevalence of hematological disorders is fuelling the expansion of the therapeutic plasma exchange market.
Request Your Free Therapeutic Plasma Exchange Market Report Sample Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=15683&type=smp
Which Companies Are Leading the Charge in Expanding the Therapeutic Plasma Exchange Market?
Major companies operating in the therapeutic plasma exchange market are:
• Medica S.p.A.
• Fresenius SE and Co. KGaA
• Medtronic Plc.
• Asahi Kasei Corporation
• Toray Industries Inc.
What New Trends Are Reshaping the Therapeutic Plasma Exchange Market and Its Opportunities?
Many key players in the therapeutic plasma exchange market are pursuing strategic partnerships as a way to augment technology integration and broaden their market presence. A strategic partnership generally implies a mutual alliance between multiple organizations wherein they amalgamate their resources, expertise, and endeavors to accomplish shared goals or objectives. For instance, in July 2022, Terumo Blood and Cell Technologies, an American technology firm, joined forces with Eliaz Therapeutics Inc., – a U.S. medical device firm adept in therapeutic apheresis for inflammatory and kidney-related diseases. They aim to address acute kidney injury (AKI) and Sepsis-induced AKI (S-AKI) through the selective removal of the inflammatory protein Gal-3 from blood plasma. Given the high mortality rates linked to AKI, the partnership intends to investigate new treatments using Terumo’s Spectra Optia Apheresis System and ETI’s XGal-3 column. Preliminary studies will be conducted on large animals before advancing to human clinical trials. Terumo, recognized for its innovation in therapeutic apheresis, has previously entered collaborative projects targeting diseases like triple-negative breast cancer and COVID-19.
Pre-order Your Report for Quick and Easy Delivery!
https://www.thebusinessresearchcompany.com/report/therapeutic-plasma-exchange-global-market-report
What Are the Primary Segments of the Therapeutic Plasma Exchange Market and Their Roles in Growth Dynamics?
The therapeutic plasma exchange market covered in this report is segmented –
1) By Type: Therapeutic Plasma Exchange (TPE), Double Filtered Plasmapheresis (DFPP)
2) By Indication: Neurological Disorders, Hematological Disorders, Renal Disorders, Metabolic Disorders, Other Indications
3) By Technology: Centrifugation, Membrane Separation
4) By End User: Blood Collection Centers, Hospitals And Clinics, Transfusion Centers, Other End Users
Subsegments:
1) By Therapeutic Plasma Exchange (Tpe): Manual Tpe, Automated Tpe
2) By Double Filtered Plasmapheresis (Dfpp): Single-Stage Dfpp, Multi-Stage Dfpp
What Are the Top Regions Fueling Growth in the Therapeutic Plasma Exchange Market?
North America was the largest region in the therapeutic plasma exchange market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the therapeutic plasma exchange market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Defines the Scope of the Therapeutic Plasma Exchange Market?
Therapeutic plasma exchange (TPE) refers to a medical procedure used to treat certain autoimmune diseases and other conditions. During TPE, blood is removed from the body, plasma (the liquid portion of the blood) is separated from the blood cells, and then the blood cells are returned to the body, often after being mixed with a replacement fluid. This process helps remove harmful substances from the blood, such as autoantibodies or toxins, which can contribute to various diseases.
Browse Through More Similar Reports By The Business Research Company:
Biosimilar Therapeutic Peptides Global Market Report 2024
Non-Therapeutic Biomolecules Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/non-therapeutic-biomolecules-global-market-report
Respiratory Devices And Equipment (Therapeutic) Global Market Report 2024
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
